Sanofi and Teva to Collaborate on Treatment for Inflammatory Bowel Disease
- Posted by ISPE Boston
- On October 12, 2023
Sanofi and Teva Pharmaceuticals have entered into a collaboration to co-develop and co-commercialize TEV’574, currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two types of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. An estimated 10 million people worldwide live with IBD. According to […]
Read More